GlobalDatas pharmaceuticals report, Rencarex (Renal Cell Carcinoma)Analysis and Forecasts to 2020 provides Rencarex sales forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

• Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
• Analysis and review of Rencarex including historical sales data
• Qualitative and quantitative assessment of market space
• Analysis of the trends, drivers and restraints shaping and defining the markets
• In-depth analysis of Rencarex including efficacy, safety, pricing, competition and other details which influence its sales potential
• Detailed sales forecast for 2015-2020 for Rencarex in each of the seven major markets

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drugs performance
• Examine the historical sales performance of a drug in seven major markets
• Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of content

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4

2 Introduction 6
2.1 RCC Market 6
2.2 Epidemology 6
2.3 Etiology 8
2.3.1 Tobacco 8
2.3.2 Obesity 8
2.3.3 Acquired Cystic Disease 9
2.3.4 Hypertension 9
2.4 GlobalData Pipeline Report Guidance 9

3 RCC Disease: Market Characterization 10
3.1 RCC Disease Market 10
3.2 RCC Disease Market Forecast and CAGR 10
3.3 Drivers for the RCC Disease Market 11
3.3.1 High Incidence 11
3.3.2 High Prevalence 12
3.3.3 Emergence of Targeted Therapies 12
3.3.4 Large Unmet Need 12

4 TNM Classification of RCC 13

5 Rencarex 16
5.1 Introduction 16
5.2 Mechanism of Action 16
5.3 Clinical Studies 17
5.4 Sales drivers 17
5.4.1 Renal Cancer Market 17
5.4.2 Large unmet need 17
5.4.3 Excellent Safety and Tumour Targeting 18
5.5 Drug Evaluation 18
5.5.1 Drug Risk Benefit Score 18
5.5.2 Intensity of Competition 19
5.6 Sales forecast 19
5.6.1 Target patient Pool of Rencarex 19
5.6.2 Market Penetration 21
5.6.3 Dosing 21
5.6.4 Annual Cost of Therapy 21
5.6.5 Sales Projections of Rencarex 22

6 RCC Market: Appendix 30
6.1 Market Definitions 30
6.2 Abberiviations 30
6.3 Research Methodology 30
6.3.1 Coverage 31
6.3.2 Secondary Research 31
6.3.3 Forecasting 32
6.3.4 Number of Patients Approved to take the Drug 32
6.3.5 Net Penetration of Drug 32
6.3.6 Net Annual Dosing 34
6.3.7 Annual Cost of Therapy 34
6.3.8 Primary Research 34
6.3.9 Expert Panels 34
6.4 Contact Us 34
6.5 Disclaimer 35
6.6 Sources 35

List of Tables

Table 1: RCC, Incidences and Mortality, 2008-2030 7
Table 2: RCC, Global, Market Size Forecast ($bn), 20092020 10
Table 3: Rencarex Clinical Trials 17
Table 4: Drug Risk Benefit Score (DRB)-Rencarex 18
Table 5: Rencarex, RCC, Global Sales Forecast ($m), 20152020 22
Table 6:Rencarex, RCC, the US Sales Forecast ($m), 20152020 23
Table 7: Rencarex, RCC, UK Sales Forecast ($m), 20152020 24
Table 8: Rencarex, RCC, France Sales Forecast ($m), 20152020 25
Table 9: Rencarex, RCC, Germany Sales Forecast ($m), 20152020 26
Table 10: Rencarex, RCC, Italy Forecast ($m), 20152020 27
Table 11: Rencarex, RCC Spain Forecast ($m), 20152020 28

List of Figures

Figure 1: % Distribution of Top 20 Diagnosed Cancers 6
Figure 2: Difference of % Distribution of Incidence and Mortality of Top 20 Cancers 8
Figure 3: Per Capita Cigarette Consumption, The US, 1976-2006 9
Figure 4: : RCC, Global, Market Size Forecast ($bn), 20092020 10
Figure 5: Oncology, Global, Incidence (in million), 2008-2030 11
Figure 6: : RCC, Global, Incidence (in million), 2008-2030 12
Figure 7: : Broad Classification of Kidney Cancer 13
Figure 8: : Detailed TNM Classifications 14
Figure 9: : Classification of RCC (US, EU except UK and Japan) 15
Figure 10: : Classification of RCC (The UK) 15
Figure 11: ADCC mechanism of action 16
Figure 12: Radioimmunoscintigrams using the 131-Iodine labelled WX-G250-antibody 18
Figure 13: Drug Model Diagram of Rencarex in the US and EU 20
Figure 14: Drug Model Diagram of Rencarex in UK 20
Figure 15: Rencarex, RCC, Global Sales Forecast ($m), 20152020 22
Figure 16: Rencarex, RCC, the US Sales Forecast ($m), 20152020 23
Figure 17: Rencarex, RCC, UK Sales Forecast ($m), 20152020 24
Figure 18: Rencarex, RCC, France Sales Forecast ($m), 20152020 25
Figure 19: Rencarex, RCC, Germany Sales Forecast ($m), 20152020 26
Figure 20: : Rencarex, RCC, Italy Sales Forecast ($m), 20152020 27
Figure 21: Rencarex, RCC, Spain Sales Forecast ($m), 20152020 28
Figure 22: Global Sales Distribution of Rencarex ($ mn), 2020 29
Figure 23: : GlobalData Methodology 30
Figure 24: Drug Model Diagram 33
Figure 25: Patients Approved for the Drug 33